H.C. Wainwright Lowers Black Diamond Therapeutics Price Target to $10, Maintains Buy Rating

Black Diamond Therapeutics' price target has been lowered to $10 from $12 by H.C. Wainwright analyst Robert Burns, who maintains a Buy rating on the shares. Burns expects another clinical update on BDTX-1535 in Q4.

Title: Black Diamond Therapeutics' Price Target Lowered by HC Wainwright

Black Diamond Therapeutics (NASDAQ: BDTX) has seen its price target lowered by HC Wainwright analyst Robert Burns from $12 to $10, while maintaining a "Buy" rating. This adjustment reflects the current market conditions and analyst expectations for the company's clinical updates. The stock remains favored by some analysts, with a consensus rating of "Moderate Buy" and a target price of $12.40 [1].

The recent earnings report for Black Diamond Therapeutics showed an EPS of ($0.19), exceeding analyst expectations of ($0.25). The company continues to focus on its pipeline of MasterKey therapies, including BDTX-1535, a brain-penetrant epidermal growth factor receptor inhibitor in phase 2 clinical trials for non-small cell lung cancer and glioblastoma. The company's financial position remains strong, with $142.8 million in cash and investments at the end of Q2 2025 [2].

Other brokerages have also provided updates on Black Diamond Therapeutics. Wall Street Zen downgraded the stock to a "hold" rating, while Raymond James Financial raised it to "outperform" with a price target of $11.00. The company is actively exploring partnership opportunities and plans to meet with the FDA in the first half of 2026 regarding the development path for its lead product candidate, silevertinib [1].

Black Diamond Therapeutics has been making significant strides in the precision oncology field, focusing on tumor-agnostic therapies targeting oncogenic mutations in cancers like NSCLC and glioblastoma. The company's MasterKey therapies aim to address resistance mechanisms, providing new treatment options for patients with genetically defined tumors [2].

Investors should keep an eye on the upcoming clinical updates, particularly the expected data for BDTX-1535 in Q4 2025. The company's strong financial position and pipeline of innovative therapies make it a company to watch in the biotechnology sector.

References:
[1] https://www.marketbeat.com/instant-alerts/black-diamond-therapeutics-nasdaqbdtx-given-new-1000-price-target-at-hc-wainwright-2025-08-11/
[2] https://www.stocktitan.net/news/BDTX/